title: Current and future treatments of secondary osteoporosis.
abstract: Osteoporosis is commonly associated with menopause and ageing. It can, however, also be caused by diseases, lifestyle, genetic diseases, drug therapies and other therapeutic interventions. In cases of secondary osteoporosis, a common rule is the management of the underlying condition. Healthy habits and calcium and vitamin D supplementation are also generally advised. In cases of high risk of fracture, specific antiosteoporosis medications should be prescribed. For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in secondary osteoporosis, and denosumab or teriparatide have been also assessed in some cases. Important research is needed to develop more tailored strategies, specific to the peculiarities of the different types of secondary osteoporosis.
authors.affiliation: Department of Internal Medicine, Hospital del Mar, Spain; Institut Hospital del Mar d'Investigacions Mèdiques, Spain; Autonomous University of Barcelona, Spain; RETICEF, Instituto Carlos III, Spain. Electronic address: 99928@parcdesalutmar.cat.
authors.forename: Raquel
authors.initials: R
authors.lastname: Soriano
authors.affiliation: Department of Internal Medicine, Hospital del Mar, Spain; Institut Hospital del Mar d'Investigacions Mèdiques, Spain; Autonomous University of Barcelona, Spain; RETICEF, Instituto Carlos III, Spain. Electronic address: 99940@parcdesalutmar.cat.
authors.forename: Sabina
authors.initials: S
authors.lastname: Herrera
authors.affiliation: Department of Internal Medicine, Hospital del Mar, Spain; Institut Hospital del Mar d'Investigacions Mèdiques, Spain; Autonomous University of Barcelona, Spain; RETICEF, Instituto Carlos III, Spain. Electronic address: 85382@parcdesalutmar.cat.
authors.forename: Xavier
authors.initials: X
authors.lastname: Nogués
authors.affiliation: Department of Internal Medicine, Hospital del Mar, Spain; Institut Hospital del Mar d'Investigacions Mèdiques, Spain; Autonomous University of Barcelona, Spain; RETICEF, Instituto Carlos III, Spain. Electronic address: adiez@parcdesalutmar.cat.
authors.forename: Adolfo
authors.initials: A
authors.lastname: Diez-Perez
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide; D000069448:Denosumab
keywords: osteoporosis; secondary osteoporosis; treatment